Is this discontinued drug from Pfizer nothing more than a drop in the bucket?
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...
CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
NEW YORK, Sept. 11, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning...
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Trillium Therapeutics Inc. (NASDAQ: TRIL) to Pfizer Inc. for $18.50 per share in cash is fair to Trillium shareholders....
WILMINGTON, Del., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Trillium Therapeutics, Inc. (“Trillium”) (NASDAQ CM: TRIL ) regarding possible breaches...
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Trillium...